DRUGS APPROVED BY THE FDA FOR WEIGHT LOSS
DRUGS APPROVED BY THE FDA FOR WEIGHT LOSS
Drugs approved for use in weight loss programs can be broken
down into the following categories:
1. Anorexiants (drugs that work on chemicals in the brain)
a. Amphetamines
1. Benzphetamine (Didrex®)
2. Diethylpriopion (Tenuate®; Tenuate Dospan®)
3. Methamphetamine (Desoxyn®)
4. Phentermine (Adipex®; Adipex®-P or Ionamin®)
b. Sibutramine (Meridia®)
2. Lipase Inhibitors (drugs [...]
Roche, GlaxoSmithKline Sign Promotional Agreement for Xenical in U.S.
Pharmaceutical giants Roche and GlaxoSmithKline have signed a promotional agreement for weight-loss medication Xenical (orlistat) in the United States, according to a statement issued April 12th.
The pact gives Glaxo exclusive rights to promote prescription Xenical in the United States. Glaxo also acquired the rights to an over-the-counter (OTC) version of the [...]
FDA Delay on Diet Pill Acomplia (Rimonabant) Tied to Suicide, Seizures
The long delay in FDA action on diet drug rimonabant ( Acomplia (rimonabant) is the result of concern over “increased frequencies of psychiatric adverse effects” including suicide and seizures, the agency’s staff disclosed on June 11th.
The confirmation of long-rumored FDA worries over the neuropsychiatric side-effects of [...]
Smoking Rimonabant
Smoking Rimonabant
On March 9, at the American College of Cardiology Scientific Sessions in New Orleans, investigators presented details of their studies with rimonabant (trade name: Acomplia) - the first of a new class of drugs (selective CB1 blockers) aimed at helping with weight loss and smoking cessation. CB1 blockers act on [...]
Acomplia Rimonabant, Zimulti Side-Effects
Much of the excitement about Acomplia / Zimulti stems from early results suggesting that it not only facilitates weight loss, but that it also helps patients significantly improve their lipid and glucose profiles.
In the RIO-Lipids trial, weight loss was accompanied by a decrease in waist size of 3.4 [...]
Diet Drug Rimonabant (Acomplia) Significant Improves Glucose Control of Diabetic Patients
Diet drug Acomplia (rimonabant) significantly improved the blood glucose control of type 2 diabetic patients in a major clinical trial called ARPEGGIO, researchers reported on June 10th at the 68th Scientific Sessions of the American Diabetes Association.
The researchers said that patients in the multicenter trial who [...]
Study: More Encouraging Two-Year Trial Results Reported for Acomplia
The new diet drug rimonabant (Acomplia), which made headlines in November with two-year trial results showing it helped people lose significantly more weight than a placebo Acomplia (rimonabant) , got a new boost today (March 8th) as researchers reported another round of highly encouraging two-year results from [...]
Acomplia Reported to Show Promise as a Treatment for Prediabetics
A new analysis of the potential of Acomplia (rimonabant) as a treatment for prediabetics was sufficiently encouraging to lead researchers to conclude that a long-term study exploring the role of the new drug in preventing Type 2 diabetes is warranted.
Dr. Julio Rosenstock of the Dallas Diabetes Center in [...]
